Management of Hematemesis in a Cirrhotic Patient with INR 2.0
A cirrhotic patient with hematemesis and INR 2.0 should be managed with immediate vasoactive drug therapy (terlipressin, somatostatin, or octreotide), antibiotic prophylaxis (ceftriaxone 1g/24h), restrictive blood transfusion (target hemoglobin 7-9 g/dL), and urgent endoscopy within 12 hours for variceal band ligation—without any correction of the INR. 1
Critical Initial Management
Immediate Pharmacotherapy (Before Endoscopy)
Start vasoactive drugs as soon as variceal hemorrhage is suspected, even before endoscopic confirmation 1:
- Terlipressin: 2 mg IV every 4 hours for first 48 hours, then 1 mg every 4 hours
- Somatostatin: 250 µg IV bolus, then 250 µg/hour continuous infusion (can increase to 500 µg/hour)
- Octreotide: 50 µg IV bolus, then 50 µg/hour continuous infusion
Continue vasoactive therapy for 3-5 days after bleeding control to prevent early rebleeding 1.
Antibiotic Prophylaxis
Ceftriaxone 1 g IV every 24 hours for up to 7 days is first-line 1. This reduces infection rates, improves bleeding control, and improves survival. Bacterial infections occur in >50% of cirrhotic patients with GI bleeding and independently predict failure to control bleeding and death.
Resuscitation Strategy
- Volume replacement with crystalloids (or colloids if needed)
- Restrictive transfusion: Transfuse only if hemoglobin <7 g/dL, with target 7-9 g/dL 1, 2
- Two large-bore (16-gauge) peripheral IV lines
- Airway protection: Consider elective intubation if severe uncontrolled bleeding, severe encephalopathy, oxygen saturation <90%, or aspiration risk 3
The INR 2.0: Do NOT Correct It
Recommendations regarding correction of coagulopathy and thrombocytopenia cannot be made based on currently available data 1. More importantly, in patients with cirrhosis and active variceal bleeding, if hemostasis is achieved with portal hypertension-lowering drugs and endoscopic treatment, correction of hemostatic abnormalities is not indicated 4.
The INR does not reflect true bleeding risk in cirrhosis because:
- Patients with cirrhosis have a rebalanced hemostatic system with simultaneous decreases in both pro- and anticoagulant factors 5, 6
- PT/INR primarily reflects liver synthetic dysfunction, not coagulability 7
- Routine correction with FFP or other blood products is not indicated and may cause harm 8, 5
Only if bleeding control fails despite combined pharmacological and endoscopic therapy should correction of hemostasis be considered on a case-by-case basis 4.
Endoscopic Management
Timing and Preparation
- Perform endoscopy within 12 hours after hemodynamic stabilization 1
- Consider erythromycin 250 mg IV 30-120 minutes before endoscopy to improve gastric visualization (unless QT prolongation) 1
- Up to 30% of cirrhotic patients bleed from non-variceal causes, so endoscopy confirms the source 1
Endoscopic Therapy
Endoscopic variceal band ligation (EVL) is the method of first choice 3:
- More effective than sclerotherapy
- Fewer adverse effects
- May improve survival
- Sclerotherapy only if ligation not feasible
The combination of endoscopic therapy plus vasoactive drugs is the current standard of care and more effective than either alone 1.
High-Risk Patients: Consider Early TIPS
Early TIPS placement (within 72 hours) should be considered in high-risk patients 2:
- Child-Pugh C (score 10-13) with active bleeding at endoscopy
- Child-Pugh B with active bleeding at endoscopy
- Hepatic venous pressure gradient (HVPG) ≥20 mmHg
Early TIPS in these populations significantly improves survival 9, 10.
Rescue Therapy for Treatment Failure
Failure to control bleeding is defined as 2:
- Fresh hematemesis ≥100 mL ≥2 hours after treatment initiation
- Development of hypovolemic shock
- 3 g drop in hemoglobin within 24 hours without transfusion
TIPS is the best rescue treatment (90% bleeding control) 2. If TIPS unavailable or not feasible:
- Balloon tamponade as bridge therapy (maximum 24 hours due to high complication risk) 2
- Self-expanding esophageal metal stent (superior to balloon tamponade with 85% vs 47% bleeding control) 2, 9
Common Pitfalls to Avoid
- Do not delay vasoactive drugs waiting for endoscopy—start immediately on clinical suspicion
- Do not overtransfuse—aggressive transfusion worsens portal pressure and rebleeding risk
- Do not routinely correct INR/platelets—this is not indicated and delays definitive therapy
- Do not forget antibiotics—they improve survival, not just prevent infection
- Do not use short-acting octreotide boluses alone—continuous infusion for 3-5 days is required
- Do not miss high-risk patients who need early TIPS—Child C 10-13 or Child B with active bleeding benefit from preemptive TIPS